NHS England has declared a pause on new dispensing of cross-sex hormones for 16 and 17-year-olds questioning their gender identity, in the wake of a comprehensive review that determined previous research into the drugs’ safety and effectiveness was inadequate. The decision, which takes effect immediately, follows an impartial assessment of evidence ordered by the health service determined there was insufficient high-quality evidence to determine whether the hormones help or damage young people. Teenagers currently on the treatment will continue their prescriptions, though clinicians will be required to assess their cases. NHS England said a limited number of young people would be impacted by the pause and will be provided with other treatment options at three NHS gender clinics for children serving England.
The Choice and Its Scope
The pause indicates a notable transition in NHS England’s handling of medical care for gender affirmation for young people. Cross-sex hormones, which help individuals acquire bodily features associated with their chosen gender, can produce irreversible changes including a deeper voice, breast development, or other permanent alterations. The decision to stop new prescriptions originates from the NHS’s evaluation that available evidence cannot definitively establish whether these treatments assist or injure young people experiencing gender dysphoria. Professor James Palmer, National Medical Director for Specialised Services at NHS England, stressed that the review had been “exceptionally thorough and complex,” finally concluding that existing evidence does not support ongoing use of masculinising or feminising hormone treatments for young people under 18.
NHS England has launched a 90-day public consultation commencing Monday to collect additional feedback on the revised policy and review findings. The NHS expects this consultation process will identify any evidence that could have been missed during the initial review process. Current guidance already banned prescriptions to under-16s seeking gender treatment, so the new pause effectively extends restrictions to cover 16 and 17-year-olds. The NHS stressed its commitment to providing full support, stating that young people who cannot receive hormone therapy will be offered alternative forms of care through its three dedicated gender clinics for children across England.
- Pause covers new prescriptions for 16 and 17-year-olds only
- Young people presently taking hormones will continue existing treatment
- Clinicians will review active cases for sustained appropriateness
- Alternative care available at three NHS gender clinics nationally
Review of Evidence Findings
The decision to pause hormone prescriptions originates from a comprehensive evidence review commissioned by NHS England, which assessed the scientific basis for cross-sex hormone treatment in adolescents. The assessment, comprising ten separate evaluations of various dimensions of testosterone and oestrogen use, uncovered notable deficiencies in the research underpinning existing clinical practice. NHS England determined that the existing evidence was inadequate to determine whether these therapies benefit or harm adolescents experiencing gender dysphoria, rendering it unfeasible to justify continuing new prescriptions with confidence in their safety and effectiveness.
This finding aligns with worries expressed in Dr Hilary Cass’s significant April 2024 review on children’s gender care, which highlighted “notably insufficient” evidence surrounding clinical treatments in this domain. The Cass report encouraged NHS England to undertake its own comprehensive evaluation of the research foundation. The resulting review focused on various outcomes for younger patients, including wellbeing quality, mental health, and overall health. Rather than delaying for further evidence to develop, NHS England opted to implement a conservative stance, halting new prescriptions while maintaining efforts to evaluate responses from patient advocates and healthcare professionals.
Study Results
The 10 separate evidence assessments examined the impact of hormone hormones covering physical and mental outcomes for young people identifying as a gender identity different from their sex at birth. Reviewers evaluated existing literature on how these treatments impacted quality of life, mental health status, and distress related to gender identity among adolescents. The process was deliberately comprehensive, aiming to examine all available evidence in assessing whether adequate evidence was available to support continued prescribing practices for under-18s.
The primary conclusion was stark: the body of evidence did not meet the threshold required to confidently recommend hormone treatment for this demographic. Professor Palmer stated that the review “demonstrated that the evidence base does not endorse the ongoing use of masculinising or feminising hormones” to treat young people under 18 with gender-related conditions. This conclusion meant NHS England could not definitively establish whether the therapies were safe or efficacious, calling for a pause pending more research and professional consultation.
- Ten independent reviews examined multiple facets of endocrine treatment
- Investigation assessed quality of life and psychological results
- Available evidence found limited to warrant ongoing treatment
- Insufficient data to show if therapies negatively affect or help adolescents
Public Response and Legal Battles
The NHS choice to suspend hormone prescriptions has prompted rapid and divided responses from across the healthcare and advocacy sectors. Trans advocacy groups have voiced firm objection to the policy change, with some organisations indicating their plans to pursue legal action against NHS England. These groups contend that the pause restricts access to potentially life-changing treatment for young people with gender dysphoria, and contend that the evidence review does not justify such a restrictive approach. The consultation phase beginning Monday will be vital in establishing whether NHS England’s position shifts or strengthens based on stakeholder feedback.
Healthcare practitioners employed in gender identity care have also weighed in on the decision, with views extending across cautious support to substantial concerns. Some healthcare providers endorse the evidence review as a necessary step to confirm treatments are adequately supported, while others worry that the pause may damage vulnerable young people who have started hormone therapy or are attempting to receive care. The 90-day review period constitutes an opportunity for these diverse voices to officially submit their perspectives, conceivably shaping whether the temporary pause transforms into permanent policy or is modified based on emerging research or professional consensus.
| Group | Position |
|---|---|
| Trans Advocacy Organisations | Opposing the pause; considering legal action against NHS England |
| Some Healthcare Professionals | Supporting cautious approach; welcoming evidence-based review |
| Other Clinicians | Concerned about harm to young people already in treatment |
| NHS England Leadership | Defending precautionary approach; seeking further consultation |
Advocacy Group Response
Trans advocacy bodies have objected to the NHS pause as unfairly restrictive and potentially damaging to vulnerable young people. These groups argue that the decision to halt fresh prescriptions conflicts with the experiences of transgender adolescents who describe enhanced mental wellbeing and standard of living after hormone therapy. They assert that the evidence review’s conclusion of “weak evidence” fails to warrant such a stringent policy, and that the pause effectively denies care to individuals requiring it most while pending complete scientific confirmation that may never materialise.
Lawsuits are expected, with advocacy groups indicating they will pursue legal proceedings to reverse or amend the treatment suspension. These organisations argue that the measure breaches the rights of youth to obtain proper treatment and could amount to discrimination based on gender identification. They highlight that individual clinical assessments ought to decide treatment access instead of across-the-board bans, and that the engagement process must genuinely consider accounts from transgender communities themselves about direct experiences with hormone therapy.
Commercial Sector and Global Framework
While NHS England puts in place its conservative approach, the private healthcare sector in the UK keeps providing hormone treatments to adolescents outside the state healthcare provision. This establishes a two-tier system where wealthier families may access treatments that the NHS has put on hold, generating questions about equal access and fairness. The divergence between NHS policy and private provision underscores broader questions about how evidence-based guidelines should apply across various healthcare environments, and whether adolescents’ access to gender-affirming care should depend on their family’s financial resources rather than clinical requirement.
Internationally, healthcare systems have adopted varying approaches to hormone treatment for young people questioning their gender. Some European countries, including Sweden and Finland, have likewise restricted restrictions on gender-affirming hormones for minors in recent years, pointing to a lack of evidence. Conversely, other nations uphold more liberal prescribing policies, with some medical organisations arguing that withholding care results in greater psychological harm. These differing global approaches underscore the genuine scientific uncertainty regarding the lasting impacts and advantages of these interventions, and suggest that consensus has not yet emerged among global medical authorities on the suitable course of treatment for adolescents with gender dysphoria.
- Private clinics in the UK persist in providing hormonal therapy to minors in spite of NHS pause
- Sweden and Finland have likewise limited hormonal medications for minors in the past few years
- International medical organisations remain divided on suitable therapeutic approaches for young people
What Comes Next
NHS England has launched a structured process to determine its future direction on gender-affirming care for teenagers uncertain about their gender. A three-month public engagement launched on Monday will seek input from patient representatives, clinical experts, and the general public on the review outcomes and updated recommendations. The health service has emphasised that this engagement process is essential for finding any information missed during initial review during the original assessment. The outcomes will determine whether the current pause on fresh prescriptions becomes enduring practice or whether treatment restarts under modified conditions.
During the consultation period, NHS England will maintain oversight of young people presently on hormone treatment, with clinicians conducting individualised reviews of each patient’s treatment plan. The three established NHS gender clinics for children will increase their range of alternative care options for those unable to obtain hormones, including psychological services and therapeutic support. Following the 90-day period, NHS England will analyse all feedback received and make a final decision regarding sustained direction. This decision will have substantial impact for many young people across England pursuing gender-affirming treatment.
The 90-Day Consultation Procedure
The consultation serves as a official chance for stakeholders to challenge or support NHS England’s initial conclusions. Campaign organisations, medical professionals, and members of the general public can provide evidence and viewpoints on whether the review correctly represents existing scientific knowledge. Trans advocacy organisations have already indicated they may pursue legal action, suggesting the consultation will be disputed. NHS England has indicated it will thoroughly examine all responses, specifically aiming to find any high-quality evidence that the initial review may have missed or underweighted in its analysis.
The 90-day window is intended to balance the requirement for detailed consideration with the urgency of providing clarity to youth and healthcare providers presently uncertain about available treatments. NHS England will compile and analyse all consultation responses before releasing its final decision on revised guidance. This longer timeframe permits healthcare professionals to share clinical experiences, academic bodies to provide supplementary research, and youth themselves to articulate how the new policies affect their wellbeing and quality of life.